Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bromodomain-containing protein 4 binding domain 1 (BRD4 BD1) is a bromodomain within the BRD4 protein, a member of the BET family. It functions as an epigenetic "reader" by recognizing and binding to acetylated lysine residues on histones, particularly H4K5AcK8Ac. This interaction plays a key role in transcriptional regulation, cell cycle progression, and chromatin remodeling. BRD4 BD1 is a validated drug target, with inhibitors like JQ1 showing promise in cancer therapy by disrupting oncogenic transcriptional programs.
Competitive inhibition of acetyl-lysine binding
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bromodomain-containing protein 4 binding domain 1 (BRD4 BD1).